Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3757994 | 0.86 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL3765963 | 0.82 | KMT2A (0.40) | MEN1CYP3A4HPGDKMT2A | |
| SCHEMBL4673339 | 0.77 | MEN1 (0.46) | TDP1MEN1CYP3A4HPGDKMT2A | |
| SCHEMBL3752388 | 0.72 | TDP1 (0.40) | NQO1BACE1TDP1MEN1CYP3A4 | |
| SCHEMBL3759822 | 0.71 | TYR (0.39) | — | |
| SCHEMBL67497 | 0.69 | BACE1 (0.54) | NQO1BACE1PTPN1TDP1MEN1 | |
| SCHEMBL3752236 | 0.67 | ALOX5AP (0.35) | MEN1KMT2A | |
| SCHEMBL3764005 | 0.67 | FTO (0.31) | MEN1KMT2A | |
| SCHEMBL3844976 | 0.67 | TYR (0.35) | CYP3A4 | |
| SCHEMBL3757837 | 0.67 | ALDH1A1 (0.50) | TDP1MEN1CYP3A4HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084650-B2 | Adamantane derivative, resin composition containing same, and optoelectronic member and sealing agent for electronic circuit using those | IDEMITSU KOSAN CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20100298491-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC MEMBER AND SEALING AGENT FOR ELECTRONIC CIRCUIT USING THOSE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| EP-1985616-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC MEMBER AND SEALING AGENT FOR ELECTRONIC CIRCUIT USING THOSE | Idemitsu Kosan Co., Ltd. (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298491-A1 | ADAMANTANE DERIVATIVE, RESIN COMPOSITION CONTAINING SAME, AND OPTOELECTRONIC MEMBER AND SEALING AGENT FOR ELECTRONIC CIRCUIT USING THOSE | AOC1, ASIC1, ICAM1 | NQO1 1347/4885BACE1 184/4885PTPN1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.